المؤلفون: Jiang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Zheng Y; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Qian J; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Mao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Xu X; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Li N; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Xiao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Wang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China., Teng L; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China., Zhou H; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China., Wang S; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China., Zhu D; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China., Peng B; Department of Translational Medicine, Innovent Biologics, Inc, Suzhou, China., Shen L; Department of Medical Oncology, Beijing Cancer Hospital, Beijing, China., Xu N; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China. Nongxu.zhjph@outlook.com.

المصدر: BMC cancer [BMC Cancer] 2020 Aug 14; Vol. 20 (1), pp. 760. Date of Electronic Publication: 2020 Aug 14.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Adenocarcinoma/*drug therapy , Antibodies, Monoclonal, Humanized/*adverse effects , Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Drug-Related Side Effects and Adverse Reactions/*epidemiology , Stomach Neoplasms/*drug therapy, Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Capecitabine/administration & dosage ; Capecitabine/adverse effects ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/etiology ; Esophagogastric Junction/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Progression-Free Survival ; Severity of Illness Index ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology

المؤلفون: Yulong Zheng, Xin Xu, Jiong Qian, Lin Shen, Haiping Jiang, Chenyu Mao, Bo Peng, Nong Xu, Shuyan Wang, Hui Zhou, Donglei Zhu, Cheng Xiao, Ning Li, Lisong Teng, Huan Wang

المصدر: BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Tumor mutation burden, Drug-Related Side Effects and Adverse Reactions, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Gastroenterology, lcsh:RC254-282, Severity of Illness Index, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Humans, Adverse effect, Aged, business.industry, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Sintilimab, Progression-Free Survival, Oxaliplatin, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, Gastric/gastroesophageal junction adenocarcinoma, Esophagogastric Junction, business, Progressive disease, medicine.drug, Research Article, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c61b22b1650b3c7112aff8c90a061748
http://europepmc.org/articles/PMC7427727